Lyrica Reviewer Concerns On Vision, Skin Led To Consults With Top FDA Staff

Top CDER officials moderated the primary reviewers' inclination to delay approval of Pfizer's Lyrica (pregabalin) until more data on dermatologic and visual effects better characterized the drug's risks, review documents show